Insights on in vitro models for safety and toxicity assessment of cosmetic ingredients

Almeida, Andreia; Sarmento, Bruno; Rodrigues, Francisca

doi:10.1016/j.ijpharm.2017.01.024

Cited by 62 publications

(42 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although IL-8 is a suitable screening metric, there is a consensus that a single biomarker or assay is unlikely to be predictive of all skin sensitizers 27,33,34 . Thus, a tiered strategy was developed that evaluates several different metrics of sensitization together to make an informed prediction.…”

Section: Discussionmentioning

confidence: 99%

Tri-culture system for pro-hapten sensitizer identification and potency classification

et al. 2018

View full text Add to dashboard Cite

Allergic contact dermatitis (ACD) is an inflammatory disease that impacts 15-20% of the general population and accurate screening methods for chemical risk assessment are needed. However, most approaches poorly predict pre- and pro-hapten sensitizers, which require abiotic or metabolic conversion prior to inducing sensitization. We developed a tri-culture system comprised of MUTZ-3-derived Langerhans cells, HaCaT keratinocytes, and primary dermal fibroblasts to mimic the cellular and metabolic environments of skin sensitization. A panel of non-sensitizers and sensitizers was tested and the secretome was evaluated. A support vector machine (SVM) was used to identify the most predictive sensitization signature and classification trees identified statistical thresholds to predict sensitizer potency. The SVM computed 91% tri-culture prediction accuracy using the top 3 ranking biomarkers (IL-8, MIP-1β, and GM-CSF) and improved the detection of pre- and pro-haptens. This in vitro assay combined with in silico data analysis presents a promising approach and offers the possibility of multi-metric analysis for enhanced ACD sensitizer screening.

show abstract

Section: Discussionmentioning

confidence: 99%

Tri-culture system for pro-hapten sensitizer identification and potency classification

et al. 2018

View full text Add to dashboard Cite

show abstract

“…A critical turning point occurred in the early 2000s with the introduction of the EU's 7th Amendment to the Cosmetics Directive. This amendment prohibited animal testing of finished products or cosmetic ingredients, introducing a marketing ban regardless of the availability of alternative nonanimal tests . Industry was thus forced to find alternatives or develop new methods.…”

Section: Relevant Applications Of Tissue Engineering In the Developmementioning

confidence: 99%

Current and Future Perspectives on Skin Tissue Engineering: Key Features of Biomedical Research, Translational Assessment, and Clinical Application

Navarro

Coburn

et al. 2019

Adv Healthcare Materials

157

View full text Add to dashboard Cite

The skin is responsible for several important physiological functions and has enormous clinical significance in wound healing. Tissue engineered substitutes may be used in patients suffering from skin injuries to support regeneration of the epidermis, dermis, or both. Skin substitutes are also gaining traction in the cosmetics and pharmaceutical industries as alternatives to animal models for product testing. Recent biomedical advances, ranging from cellular‐level therapies such as mesenchymal stem cell or growth factor delivery, to large‐scale biofabrication techniques including 3D printing, have enabled the implementation of unique strategies and novel biomaterials to recapitulate the biological, architectural, and functional complexity of native skin. This progress report highlights some of the latest approaches to skin regeneration and biofabrication using tissue engineering techniques. Current challenges in fabricating multilayered skin are addressed, and perspectives on efforts and strategies to meet those limitations are provided. Commercially available skin substitute technologies are also examined, and strategies to recapitulate native physiology, the role of regulatory agencies in supporting translation, as well as current clinical needs, are reviewed. By considering each of these perspectives while moving from bench to bedside, tissue engineering may be leveraged to create improved skin substitutes for both in vitro testing and clinical applications.

show abstract

“…Changes in legislation, specifically in the European Union, have encouraged the creation of in vitro tests so as to evaluate the safety of cosmetic ingredients, since the use of animal tests was prohibited in Europe in 2004 for cosmetics and in 2009 for cosmetic ingredients [38]. A recent review by Almeida et al [38] has provided insights into the in vitro models for safety and toxicity assessments of cosmetic ingredients and some of the in vitro tests currently accepted by the Organization for Economic Co-operation and Development. Traditional in vivo tests are listed in ▶ Table 2. ▶ Table 2 In vivo and In vitro tests employed for the safety assessment of cosmetics.…”

Section: Cosmeceutical Developmentmentioning

confidence: 99%

“…Traditional in vivo tests are listed in ▶ Table 2. ▶ Table 2 In vivo and In vitro tests employed for the safety assessment of cosmetics. With information from [38,39].…”

Section: Cosmeceutical Developmentmentioning

confidence: 99%

“…Finally, as mentioned above, new regulations, specifically in the European Union, have restricted the use of in vivo testing to assess the safety of cosmetic ingredients, which has resulted in the creation of new in vitro methods [38]. In the coming years, we expect emerging countries in South America, Asia, and Africa to implement more such regulations.…”

Section: Perspectives In Cosmeceutical Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Current Methods for the Discovery of New Active Ingredients from Natural Products for Cosmeceutical Applications

Espinosa-Leal

García‐Lara

2019

Planta Med

View full text Add to dashboard Cite

Cosmeceuticals are designed to serve a dual purpose: to provide desired esthetical effects and to treat dermatological conditions. Natural products derived from plants and marine organisms are a novel source of potential cosmeceutical active ingredients for incorporation into new formulations due to consumer demands. Contrary to common perceptions, most regulatory agencies do not view cosmeceuticals as being a separate category from cosmetics; thus, these products are not regulated accordingly, thereby forcing the consumer to rely on the self-regulatory policies of the cosmetics industry. Cosmeceuticals are advertised as having capabilities that include anti-aging, anti-acne, solar-protective, wound healing, and skin whitening. Such traits normally comprise several biological activities. In order to ensure the safety and efficacy of these products, active ingredients employed in the formulations must undergo a series of tests. In this review, in vitro (enzymatic and cellular) and in vivo tests employed to evaluate the potential of new cosmeceutical active ingredients are discussed, and new trends that are being explored by the cosmeceutical industry are described.

show abstract

Insights on in vitro models for safety and toxicity assessment of cosmetic ingredients

Cited by 62 publications

References 35 publications

Tri-culture system for pro-hapten sensitizer identification and potency classification

Tri-culture system for pro-hapten sensitizer identification and potency classification

Current and Future Perspectives on Skin Tissue Engineering: Key Features of Biomedical Research, Translational Assessment, and Clinical Application

Current Methods for the Discovery of New Active Ingredients from Natural Products for Cosmeceutical Applications

Contact Info

Product

Resources

About